Do analysts prefer PRTC or ERGO?

PureTech Health presently has a consensus price target of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher probable upside, research analysts plainly believe PureTech Health is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PRTC or ERGO?

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £4.66M 65.00 -£91.86M -£46.00 N/A Ergomed £152.09M 0.00 £15M £0.29 N/A

Is PRTC or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health -2,355.32% -31.98% -13.39% Ergomed 9.87% 18.08% 10.16%

Do analysts recommend PRTC or SLN?

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts clearly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer PRTC or HZD?

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

PureTech Health (PRTC) Competitors

GBX 124.40 -1.80 (-1.43%)

As of 12:09 PM Eastern

Compare

PRTC vs. OXB, ERGO, SLN, AVCT, and HZD

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), Avacta Group (AVCT), and Horizon Discovery Group plc (HZD.L) (HZD). These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Biomedica?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Oxford Biomedica had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Oxford Biomedica	Neutral

34.0% of PureTech Health shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.00	-£91.86M	-£46.00	N/A
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

PureTech Health has a beta of 0.788, indicating that its share price is 21% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.096, indicating that its share price is 10% more volatile than the broader market.

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 308.36%. Oxford Biomedica has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given PureTech Health's stronger consensus rating and higher probable upside, research analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Oxford Biomedica beats PureTech Health on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Ergomed?

PureTech Health (LON:PRTC) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

34.0% of PureTech Health shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Ergomed	Neutral

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Ergomed	9.87%	18.08%	10.16%

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.00	-£91.86M	-£46.00	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

PureTech Health presently has a consensus price target of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher probable upside, research analysts plainly believe PureTech Health is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PureTech Health has a beta of 0.788, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Summary

Ergomed beats PureTech Health on 10 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.00	-£91.86M	-£46.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts clearly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Silence Therapeutics	Neutral

34.0% of PureTech Health shares are held by institutional investors. 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

PureTech Health beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Avacta Group has higher earnings, but lower revenue than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,796.87	-£30.08M	-£9.66	N/A
PureTech Health	£4.66M	65.00	-£91.86M	-£46.00	N/A

Avacta Group currently has a consensus price target of GBX 99, suggesting a potential upside of 42.56%. PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

2.9% of Avacta Group shares are held by institutional investors. Comparatively, 34.0% of PureTech Health shares are held by institutional investors. 49.1% of Avacta Group shares are held by company insiders. Comparatively, 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.788, suggesting that its stock price is 21% less volatile than the broader market.

In the previous week, Avacta Group's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
PureTech Health	Neutral

Summary

PureTech Health beats Avacta Group on 7 of the 12 factors compared between the two stocks.

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

PureTech Health (LON:PRTC) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 308.36%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

34.0% of PureTech Health shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.00	-£91.86M	-£46.00	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Summary

PureTech Health beats Horizon Discovery Group plc (HZD.L) on 6 of the 11 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£302.81M	£444.30M	£6.49B	£2.74B
Dividend Yield	N/A	3.86%	2.67%	6.16%
P/E Ratio	-2.70	3.15	23.92	366.44
Price / Sales	65.00	6,458.64	507.57	87,084.52
Price / Cash	2.14	13.13	26.99	27.85
Price / Book	1.10	83.79	10.28	7.61
Net Income	-£91.86M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-6.61%	-2.35%	-1.43%	-0.95%
1 Month Performance	-2.20%	0.92%	3.27%	1.56%
1 Year Performance	-10.50%	64.13%	23.37%	72.41%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	1.4849 of 5 stars	GBX 124.40 -1.4%	GBX 508 +308.4%	-9.2%	£302.81M	£4.66M	N/A	300	Gap Down
OXB Oxford Biomedica	0.8367 of 5 stars	GBX 628 +0.2%	GBX 687 +9.4%	+83.4%	£759.37M	£168.74M	N/A	891	Gap Down
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.6868 of 5 stars	GBX 79 +4.6%	GBX 99 +25.3%	+120.6%	£358.27M	£113K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. OXB, ERGO, SLN, AVCT, and HZD

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Ergomed?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. OXB, ERGO, SLN, AVCT, and HZD

How does PureTech Health compare to Oxford Biomedica?

Does the media refer more to PRTC or OXB?

Do insiders and institutionals hold more shares of PRTC or OXB?

Which has better earnings & valuation, PRTC or OXB?

Is PRTC or OXB more profitable?

Which has more risk & volatility, PRTC or OXB?

Do analysts rate PRTC or OXB?

Summary

How does PureTech Health compare to Ergomed?

Do insiders & institutionals have more ownership in PRTC or ERGO?

Does the media favor PRTC or ERGO?

Is PRTC or ERGO more profitable?

Which has higher earnings and valuation, PRTC or ERGO?

Do analysts prefer PRTC or ERGO?

Which has more volatility and risk, PRTC or ERGO?

Summary

How does PureTech Health compare to Silence Therapeutics?

Is PRTC or SLN more profitable?

Which has higher valuation & earnings, PRTC or SLN?

Do analysts recommend PRTC or SLN?

Does the media refer more to PRTC or SLN?

Do insiders and institutionals have more ownership in PRTC or SLN?

Summary

How does PureTech Health compare to Avacta Group?

Which has higher valuation and earnings, AVCT or PRTC?

Do analysts rate AVCT or PRTC?

Do insiders & institutionals hold more shares of AVCT or PRTC?

Is AVCT or PRTC more profitable?

Which has more volatility and risk, AVCT or PRTC?

Does the media refer more to AVCT or PRTC?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Do analysts prefer PRTC or HZD?

Is PRTC or HZD more profitable?

Does the media refer more to PRTC or HZD?

Do insiders & institutionals hold more shares of PRTC or HZD?

Which has stronger valuation and earnings, PRTC or HZD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools